MX2019005202A - Formulaciones inyectables de capsaicina acuosa estable y usos medicos de los mismos. - Google Patents
Formulaciones inyectables de capsaicina acuosa estable y usos medicos de los mismos.Info
- Publication number
- MX2019005202A MX2019005202A MX2019005202A MX2019005202A MX2019005202A MX 2019005202 A MX2019005202 A MX 2019005202A MX 2019005202 A MX2019005202 A MX 2019005202A MX 2019005202 A MX2019005202 A MX 2019005202A MX 2019005202 A MX2019005202 A MX 2019005202A
- Authority
- MX
- Mexico
- Prior art keywords
- injectable formulations
- stable aqueous
- medical uses
- aqueous capsaicin
- capsaicin injectable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invencion proporciona formulaciones acuosas estables e inyectables de capsaicina, una dosis unitaria que contiene tales formulaciones inyectables, kits médicos y metodos para usar tales formulaciones inyectables, asi como formas farmaceuticas de dosis unitarias para el tratamiento de pacientes que sufren dolor, como dolor osteoartritico en las rodillas. Las formulaciones acuosas estables e inyectables de capsaicina pueden contener, por ejemplo, capsaicina, un agente solubilizante (por ejemplo, un ester de polietilenglicol de un ácido hidroxialcanoico (C15-C25)), un antioxidante y agua.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662416345P | 2016-11-02 | 2016-11-02 | |
PCT/US2017/059628 WO2018085476A1 (en) | 2016-11-02 | 2017-11-02 | Stable aqueous capsaicin injectable formulations and medical uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019005202A true MX2019005202A (es) | 2019-10-14 |
Family
ID=62077165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019005202A MX2019005202A (es) | 2016-11-02 | 2017-11-02 | Formulaciones inyectables de capsaicina acuosa estable y usos medicos de los mismos. |
Country Status (12)
Country | Link |
---|---|
US (6) | US11000490B2 (es) |
EP (1) | EP3534961A4 (es) |
JP (1) | JP7100635B2 (es) |
KR (1) | KR102657458B1 (es) |
CN (1) | CN110035740B (es) |
AU (1) | AU2017353782B2 (es) |
BR (1) | BR112019008239A2 (es) |
CA (1) | CA3041121A1 (es) |
IL (1) | IL266279B2 (es) |
MX (1) | MX2019005202A (es) |
NZ (1) | NZ752750A (es) |
WO (1) | WO2018085476A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3041121A1 (en) | 2016-11-02 | 2018-05-11 | Centrexion Therapeutics Corporation | Stable aqueous capsaicin injectable formulations and medical uses thereof |
EP3654961A4 (en) | 2017-07-20 | 2021-04-21 | Centrexion Therapeutics Corporation | METHODS AND COMPOSITIONS FOR TREATMENT OF PAIN WITH CAPSAICIN |
EP3840739A4 (en) * | 2018-08-24 | 2022-05-18 | Centrexion Therapeutics Corporation | SEQUENTIAL DOSING METHOD OF CAPSAICIN FOR THE TREATMENT OF KNEE JOINT PAIN |
KR20210151949A (ko) | 2020-04-05 | 2021-12-14 | 화이자 인코포레이티드 | Covid-19의 치료를 위한 화합물 및 방법 |
CN113855626B (zh) * | 2020-08-07 | 2023-03-24 | 北京泰德制药股份有限公司 | 一种用于骨关节炎治疗的辣椒碱注射剂及其制备方法 |
WO2023027670A2 (en) * | 2021-08-23 | 2023-03-02 | Tum Ekip Ilac Anonim Sirketi | Lyophilized levosimendan compositions |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4599342A (en) | 1984-01-16 | 1986-07-08 | The Procter & Gamble Company | Pharmaceutical products providing enhanced analgesia |
US5099030A (en) | 1987-03-09 | 1992-03-24 | The Procter & Gamble Company | Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain |
US5021450A (en) | 1989-05-30 | 1991-06-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof |
US5431914A (en) | 1992-04-17 | 1995-07-11 | Adekunle; Michael | Method of treating an internal condition by external application of capsaicin without the need for systemic absorption |
US5318960A (en) | 1992-06-03 | 1994-06-07 | Frank Toppo | System for transdermal delivery of pain relieving substances |
US5985860A (en) | 1992-06-03 | 1999-11-16 | Toppo; Frank | System for transdermal delivery of pain relieving substances |
EP0646372B1 (de) | 1993-09-30 | 1999-03-31 | Medichemie Ag | Capsaicin enthaltendes Arzneimittel zur Behandlung chronischer Rhinopathie |
US6248788B1 (en) | 1996-11-06 | 2001-06-19 | The Regents Of The University Of California | Therapeutic method with capsaicin and capasicin analogs |
AU5460598A (en) | 1996-11-15 | 1998-06-03 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Pharmaceutical compositions containing vanilloid agonists in combination with vanilloid antagonists |
US6060060A (en) | 1997-01-31 | 2000-05-09 | Bmb Patent Holding Corporation | Analgesic compositions from sweet peppers and methods of use thereof |
DE69806246T3 (de) | 1997-03-13 | 2006-05-18 | Campbell, James N. | Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika |
AU7799398A (en) | 1997-05-27 | 1998-12-30 | Algos Pharmaceutical Corporation | Analgesic drug composition containing a capsaicinoid and potentiator therefor |
CA2442049C (en) | 2001-03-22 | 2010-06-01 | Michael J. Iadarola | Selective ablation of pain-sensing neurons by administration of a vanilloid receptor agonist |
US20040146590A1 (en) | 2001-03-22 | 2004-07-29 | Iadarola Michael J | Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin |
US20030104085A1 (en) | 2001-12-05 | 2003-06-05 | Yeomans David C. | Methods and compositions for treating back pain |
AU2002317127A1 (en) | 2002-07-19 | 2004-02-09 | Mestex Ag | Use of neurotoxic substances for the production of a means for the treatment of joint pain and method for application of said means |
MXPA05006670A (es) | 2002-12-18 | 2005-10-19 | Algorx Pharmaceuticals Inc | Administracion de capsaicinoides. |
US20040186182A1 (en) | 2002-12-18 | 2004-09-23 | Algorx | Administration of capsaicinoids |
WO2004091521A2 (en) | 2003-04-10 | 2004-10-28 | Neurogesx, Inc. | Methods and compositions for administration of trpv1 agonists |
WO2005058283A2 (en) | 2003-12-19 | 2005-06-30 | Novo Nordisk Health Care Ag | Stabilised compositions of factor vii polypeptides |
US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
WO2006058140A2 (en) * | 2004-11-24 | 2006-06-01 | Algorx Pharmaceuticals, Inc. | Capsaicinoid gel formulation and uses thereof |
ATE489086T1 (de) | 2004-12-22 | 2010-12-15 | Mestex Ag | Mischung eines vanilloidrezeptoragonisten mit einer nervenregenerationshemmenden substanz, ihre verwendung für die herstellung eines schmerzmittels und verfahren zur applikation dieses mittels |
SI1830835T1 (sl) | 2004-12-28 | 2012-07-31 | Mestex Ag | Uporaba agonista vaniloidnega receptorja skupaj zglikozaminoglikanom ali proteoglikanom za proizvodnjo agensa za zdravljenje bolečin v sklepih in metoda in apliciranje omenjenega agensa |
WO2006069451A1 (de) | 2004-12-28 | 2006-07-06 | Mestex Ag | Verwendung von resiniferatoxin (rtx) für die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels |
US20080160487A1 (en) | 2006-12-29 | 2008-07-03 | Fairfield Language Technologies | Modularized computer-aided language learning method and system |
US8222564B2 (en) | 2008-02-13 | 2012-07-17 | Tyco Healthcare Group, Lp | Methods of altering surgical fiber |
US8158682B2 (en) | 2008-09-12 | 2012-04-17 | Vallinex, Inc. | Instillation administration of capsaicinoids for the treatment of pain |
EP2334285A1 (en) | 2008-09-12 | 2011-06-22 | Critical Pharmaceuticals Limited | Improvements in the absorption of therapeutic agents across mucosal membranes or the skin |
CN101507818B (zh) | 2008-12-15 | 2010-11-10 | 中国人民武装警察部队医学院 | 辣椒碱β-环糊精包合物及包合物的脂质体及凝胶 |
US8637569B2 (en) | 2009-10-22 | 2014-01-28 | Api Genesis, Llc | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds |
US20130303495A1 (en) | 2009-12-31 | 2013-11-14 | Sov Therapeutics | Emulsion formulations |
TW201302681A (zh) | 2011-03-25 | 2013-01-16 | Abbott Lab | Trpv1拮抗劑 |
US8889659B2 (en) | 2011-09-09 | 2014-11-18 | Api Genesis, Llc | Pain relief compositions, manufacture and uses |
ES2699806T3 (es) | 2012-04-18 | 2019-02-12 | SpecGx LLC | Composiciones farmacéuticas, disuasivas del abuso, de liberación inmediata |
ES2644935T3 (es) | 2012-04-18 | 2017-12-01 | Mallinckrodt Llc | Composiciones farmacéuticas de liberación inmediata con propiedades disuasorias del abuso |
GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
US11154535B2 (en) | 2012-07-31 | 2021-10-26 | Egis Pharmaceuticals Plc | Transdermal formulation containing COX inhibitors |
WO2014019095A1 (de) | 2012-08-03 | 2014-02-06 | Mestex Ag | Resiniferatoxin-lösung |
CN105101949A (zh) | 2012-11-12 | 2015-11-25 | Api起源有限责任公司 | 水基辣椒素类物质制剂及其制备方法和应用 |
GB201304662D0 (en) | 2013-03-14 | 2013-05-01 | Sigmoid Pharma Ltd | Compositions |
EP2961384B1 (en) | 2013-02-28 | 2019-08-28 | Basf As | A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same |
US9956166B2 (en) | 2013-09-18 | 2018-05-01 | Sorrento Therapeutics, Inc. | Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin |
GB201317756D0 (en) | 2013-10-08 | 2013-11-20 | Critical Pharmaceuticals Ltd | New process |
GB201319792D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
US20150133561A1 (en) * | 2013-11-12 | 2015-05-14 | Vizuri Health Sciences Llc | Aqueous based capsaicinoid formulations and methods of manufacture and use |
EP3096740B1 (en) | 2014-01-24 | 2020-09-30 | Sentiss Pharma Private Limited | Pharmaceutical composition comprising brinzolamide |
SG11201608383WA (en) | 2014-04-14 | 2016-11-29 | Flex Pharma Inc | Ion channel activators and methods of use |
WO2015160842A1 (en) * | 2014-04-14 | 2015-10-22 | Flex Pharma, Inc. | Methods and formulatiions of capsaicinoids and capsinoids |
WO2015160941A1 (en) | 2014-04-15 | 2015-10-22 | Vizuri Health Sciences Llc | Topical compositions for pain relief, manufacture and use |
CN105030760B (zh) | 2014-04-24 | 2018-10-02 | 长弘生物科技股份有限公司 | 稳定医药组合物 |
WO2015198350A1 (en) | 2014-06-25 | 2015-12-30 | Synergia Bio Sciences Private Limited | A pharmaceutical oil-in-water nano-emulsion |
AU2015278900B2 (en) | 2014-06-25 | 2019-04-04 | NuCana plc | Formulation comprising a gemcitabine-prodrug |
WO2016025977A1 (en) | 2014-08-19 | 2016-02-25 | Muzari Mandishora Israel | Capsaicinoids and uses thereof as medicaments |
US20180311189A1 (en) | 2014-11-13 | 2018-11-01 | Centrexion Therapeutics Corporation | Capsaicinoids for Use in Treating ACRAL Lick Granuloma |
US9359316B1 (en) | 2014-11-25 | 2016-06-07 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists |
US20180021286A1 (en) | 2015-02-02 | 2018-01-25 | Enspire Group LLC | Stabilized dialkyl fumarate compositions |
BR112017025739A2 (pt) | 2015-05-29 | 2018-08-07 | Sun Pharmaceutical Ind Ltd | composição farmacêutica oral de isotretinoína que tem biodisponibilidade aumentada, processo para preparar a mesma e método de tratamento |
CA2987114A1 (en) | 2015-06-03 | 2016-12-08 | Triastek, Inc. | Method of 3d printing oral dosage forms having a drug in a compartment sealed by an erodible plug |
US20200261409A1 (en) | 2015-11-20 | 2020-08-20 | Sorrento Therapeutics, Inc. | Methods for pain treatment using resiniferatoxin |
US9989978B2 (en) | 2016-01-21 | 2018-06-05 | Itt Manufacturing Enterprises Llc | Natural gas pressure regulator having adjustable valve seat |
CN108697673A (zh) | 2016-01-22 | 2018-10-23 | 中枢疗法公司 | 用于治疗莫顿神经瘤疼痛的辣椒碱依次给予方法 |
US10851123B2 (en) | 2016-02-23 | 2020-12-01 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists |
CA3025268A1 (en) | 2016-05-25 | 2017-11-30 | Concentric Analgesics, Inc. | Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia |
CA3041121A1 (en) | 2016-11-02 | 2018-05-11 | Centrexion Therapeutics Corporation | Stable aqueous capsaicin injectable formulations and medical uses thereof |
WO2018217937A1 (en) | 2017-05-24 | 2018-11-29 | Concentric Analgesics, Inc. | Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia |
-
2017
- 2017-11-02 CA CA3041121A patent/CA3041121A1/en active Pending
- 2017-11-02 WO PCT/US2017/059628 patent/WO2018085476A1/en active Application Filing
- 2017-11-02 NZ NZ752750A patent/NZ752750A/en unknown
- 2017-11-02 EP EP17868308.2A patent/EP3534961A4/en active Pending
- 2017-11-02 US US16/342,652 patent/US11000490B2/en active Active
- 2017-11-02 AU AU2017353782A patent/AU2017353782B2/en active Active
- 2017-11-02 BR BR112019008239A patent/BR112019008239A2/pt unknown
- 2017-11-02 CN CN201780075307.XA patent/CN110035740B/zh active Active
- 2017-11-02 KR KR1020197015747A patent/KR102657458B1/ko active IP Right Grant
- 2017-11-02 JP JP2019522974A patent/JP7100635B2/ja active Active
- 2017-11-02 MX MX2019005202A patent/MX2019005202A/es unknown
-
2019
- 2019-04-28 IL IL266279A patent/IL266279B2/en unknown
- 2019-05-01 US US16/400,278 patent/US10493047B2/en active Active
- 2019-11-26 US US16/695,831 patent/US10765649B2/en active Active
- 2019-11-26 US US16/695,824 patent/US10772853B2/en active Active
-
2020
- 2020-09-11 US US17/018,148 patent/US11344516B2/en active Active
-
2022
- 2022-03-22 US US17/701,160 patent/US11992470B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20200046656A1 (en) | 2020-02-13 |
KR20190101368A (ko) | 2019-08-30 |
US11344516B2 (en) | 2022-05-31 |
US20200093766A1 (en) | 2020-03-26 |
WO2018085476A1 (en) | 2018-05-11 |
RU2019116788A3 (es) | 2021-02-25 |
JP7100635B2 (ja) | 2022-07-13 |
US20220211649A1 (en) | 2022-07-07 |
US10772853B2 (en) | 2020-09-15 |
US11992470B2 (en) | 2024-05-28 |
IL266279B1 (en) | 2023-03-01 |
CA3041121A1 (en) | 2018-05-11 |
IL266279B2 (en) | 2023-07-01 |
JP2019537589A (ja) | 2019-12-26 |
IL266279A (en) | 2019-06-30 |
EP3534961A1 (en) | 2019-09-11 |
US20210052522A1 (en) | 2021-02-25 |
CN110035740A (zh) | 2019-07-19 |
NZ752750A (en) | 2023-05-26 |
US10765649B2 (en) | 2020-09-08 |
RU2019116788A (ru) | 2020-12-03 |
CN110035740B (zh) | 2023-08-04 |
US20200093765A1 (en) | 2020-03-26 |
BR112019008239A2 (pt) | 2019-07-16 |
US20190254996A1 (en) | 2019-08-22 |
US11000490B2 (en) | 2021-05-11 |
AU2017353782B2 (en) | 2022-06-02 |
US10493047B2 (en) | 2019-12-03 |
AU2017353782A1 (en) | 2019-05-16 |
EP3534961A4 (en) | 2020-05-27 |
KR102657458B1 (ko) | 2024-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ752750A (en) | Stable aqueous capsaicin injectable formulations and medical uses thereof | |
MX2022001755A (es) | Compuestos de dinucleotidos ciclicos y metodos de uso. | |
MX2022000270A (es) | Dispositivo para el suministro de una composicion para el cuidado de la piel. | |
MY188749A (en) | Compositions comprising a combination of nivolumab and ipilimumab | |
MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
MX2016015636A (es) | Formulaciones cannabinoides estables. | |
PH12014501560A1 (en) | Carbamate compounds and of making and using same | |
MX2016012262A (es) | Cenicriviroc para el tratamiento de fibrosis. | |
PH12016500296A1 (en) | Sodium channel modulators for the treatment of pain and diabetes | |
MX2021000289A (es) | Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia. | |
EP3808367A3 (en) | Targeting aneurysm disease by modulating phagocytosis pathways | |
UA118261C2 (uk) | Хімічні сполуки | |
DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
MX2023001963A (es) | Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino. | |
BR112016027435A2 (pt) | formulação inovadora de meloxicam | |
CL2019003533A1 (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
NZ728796A (en) | Aqueous formulation comprising paracetamol and ibuprofen | |
BR112018070626A2 (pt) | formulação farmacêutica, e, composto ou composição para uso, uso, método ou composição | |
PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
MX2020008275A (es) | Metodos para tratar trastornos mitocondriales. | |
MX2017010277A (es) | Cenicriviroc para el tratamiento de la fibrosis. | |
MX2019008847A (es) | Profarmacos de cisteamina. | |
MX2016010577A (es) | Inhaladores de dosis medida presurizados y metodo de fabricacion. | |
BR112015000647A2 (pt) | composições orais líquidas e pediátricas que contêm nepadutant | |
EP3813687A4 (en) | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF THROMBOSIS AND ADMINISTRATION BY MEDICAL DEVICES |